© 2022 MJH Life Sciences and Urology Times. All rights reserved.
© 2022 MJH Life Sciences™ and Urology Times. All rights reserved.
May 30, 2022
“I think the one thing that we're hopeful for is that people will start to look at vitamin D as a potential chemoprevention agent,” says Adam B. Murphy, MD, MBA, MSCI.
May 24, 2022
"We wanted to implement an opioid minimization pathway that was easy to follow and successful,” says Aaron Laviana, MD.
May 21, 2022
The study showed that the PSMA-targeting fluorophore IS-002 enabled enhanced intraoperative tumor detection during robotic prostatectomy.
May 18, 2022
The utilization of sabizabulin in patients yielded significant and durable objective tumor responses, according to results of a phase 1b/2 trial (NCT03752099) presented at the 2022 AUA Annual Meeting.
IS-002, an investigational, near-infrared, PSMA-targeting fluorophore, enhanced intraoperative cancer visualization during robotic prostatectomy.
May 16, 2022
Adding darolutamide to androgen deprivation therapy and docetaxel did not increase the incidence or severity of adverse events in patients with metastatic hormone-sensitive prostate cancer.
The study data strongly support PSA screening, particularly in Black men, for whom there is a paucity of clinical trial evidence, according to lead author Spyridon Basourakos, MD.
In the phase 3 SPOTLIGHT trial, PET imaging with 18F-rhPSMA-7.3 frequently led to post-scan disease upstaging compared with baseline conventional imaging in men with prostate cancer recurrence.
“Focal therapy represents a middle ground between active surveillance and more radical options,” says Rafael Sanchez-Salas, MD.
May 15, 2022
The benefit with darolutamide was observed, regardless of whether or not patients had prior local therapy.